Rallybio Corporation
RLYB
$14.35
$0.322.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 858.00K | 674.00K | 761.00K | 848.00K | 636.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 858.00K | 674.00K | 761.00K | 848.00K | 636.00K |
| Cost of Revenue | 14.14M | 15.87M | 19.97M | 20.12M | 25.33M |
| Gross Profit | -13.28M | -15.20M | -19.21M | -19.27M | -24.70M |
| SG&A Expenses | 14.33M | 14.31M | 15.44M | 15.63M | 17.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.92M | 35.63M | 40.86M | 47.93M | 54.53M |
| Operating Income | -33.06M | -34.96M | -40.10M | -47.08M | -53.90M |
| Income Before Tax | -8.98M | -14.17M | -41.65M | -48.19M | -57.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.98 | -14.17 | -41.65 | -48.19 | -57.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.98M | -14.17M | -41.65M | -48.19M | -57.78M |
| EBIT | -33.06M | -34.96M | -40.10M | -47.08M | -53.90M |
| EBITDA | -32.97M | -34.84M | -39.99M | -46.96M | -53.77M |
| EPS Basic | -1.60 | -2.55 | -7.45 | -8.67 | -10.71 |
| Normalized Basic EPS | -3.50 | -3.72 | -4.32 | -5.07 | -5.95 |
| EPS Diluted | -1.60 | -2.55 | -7.45 | -8.67 | -10.71 |
| Normalized Diluted EPS | -3.50 | -3.72 | -4.32 | -5.07 | -5.95 |
| Average Basic Shares Outstanding | 22.52M | 22.42M | 22.36M | 22.27M | 21.77M |
| Average Diluted Shares Outstanding | 22.52M | 22.42M | 22.36M | 22.27M | 21.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |